The synthesis of l-carvone and limonene derivatives with increased antiproliferative effect and activation of ERK pathway in prostate cancer cells

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 19, 2006, Pages 6539-6547

  Chen, Jiaojiao ^a   Lu, Min ^b   Jing, Yongkui ^b   Dong, Jinhua ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiproliferative effect; ERK; l Carvone; l Limonene; Prostate cancer; Synthesis

Indexed keywords

2 METHYL 5 [1 (PIPERIDIN 1 YLMETHYL)VINYL]CYCLOHEX 2 ENONE; 2 METHYL 5 [1 (PYRROLIDIN 1 YLMETHYL)VINYL]CYCLOHEX 2 ENONE; 2 METHYL 5 [1 [(2 THIOPHEN 2 YLETHYLAMINO)METHYL]VINYL]CYCLOHEX 2 ENONE; 2 METHYL 5 [[1 (4 METHYLPIPERAZIN 1 YL)METHYL]VINYL]CYCLOHEX 2 ENONE; 4 (2 METHOXYPHENYL)PIPERAZINE; 4 AMINOBENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; 4 BROMOBENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; 4 CHLOROBENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; 4 FLUOROBENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; 4 METHOXYBENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; 4 METHYLBENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; 5 (1 CYCLOHEXYLAMINOMETHYL)VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 (1 DIMETHYLAMINOMETHYL)VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 (4 BENZYLPIPERAZIN 1 YL)METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 (4 ETHYLPIPERAZIN 1 YL)METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 (4 ISOBUTYLPIPERAZIN 1 YL)METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 (4 ISOPROPYLPIPERAZIN 1 YL)METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 (ADAMANTAN 1 YLAMINO)METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 [4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; 5 [1 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL]VINYL 2 METHYLCYCLOHEX 2 ENONE; ANTINEOPLASTIC AGENT; BENZOIC ACID 2 (4 METHYL 5 OXOCYCLOHEX 3 ENYL)ALLYL ESTER; CARVEOL; CARVONE; CYCLIN DEPENDENT KINASE INHIBITOR 1; LIMONENE; MITOGEN ACTIVATED PROTEIN KINASE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHLORINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DERIVATIZATION; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; PROSTATE CANCER; PROTEIN INDUCTION; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; REDUCTION; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

ACTINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOHEXENES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESYLTRANSTRANSFERASE; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MITOGEN-ACTIVATED PROTEIN KINASES; MONOTERPENES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33747163070     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.06.013     Document Type: Article

References (23)

1. Crowell P.L., and Gould M.N. Crit. Rev. Oncog. 5 (1994) 1-22
2. Elson C.E. J. Nutr. 125 (1995) 1666S-1672S
3. Elson C.E., Peffley D.M., Hentosh P., and Mo H. Proc. Soc. Exp. Biol. Med. 221 (1999) 294-311
4. Haag J.D., Lindstrom M.J., and Gould M.N. Cancer Res. 52 (1992) 4021-4026
5. Mills J.J., Chari R.S., Boyer I.J., Gould M.N., and Jirtle R.l. Cancer Res. 55 (1995) 979-983
6. Haag J.D., and Gould M.N. Cancer Chemother. Pharmacol. 34 (1994) 477-483
7. Hardcastle I.R., Rowlands M.G., Barber A.M., Grimshaw R.M., Mohan M.K., et al. Biochem. Pharmacol. 57 (1999) 801-809
8. Gelb M.H., Tamanoi F., Yokoyama K., Ghomashchi F., Esson K., et al. Cancer Lett. 91 (1995) 169-175
9. Crowell P.L., Ren Z., Lin S., Vedejs E., and Gould M.N. Biochem. Pharmacol. 47 (1994) 1405-1415
10. Vigushin D.M., Poon G.K., Boddy A., English J., Halbert G.W., Pagonis C., Jarman M., and Coombes R.C. Cancer Chemother. Pharmacol. 42 (1998) 111-117
11. Hudes G.R., Szarka C.E., Adams A., Ranganathan S., McCauley R.A., et al. Clin. Cancer Res. 6 (2000) 3071-3080
12. Liu G., Oettel K., Bailey H., Van Ummersen L., Tutsch K., Staab M.J., Horvath D., Alberti D., Arzoomanian R., Rezazadeh H., McGovern J., Robinson E., DeMets D., and Wilding G. Invest. New Drugs 21 (2003) 367-372
13. Meadows S.M., Mulkerin D., Berlin J., Bailey H., Kolesar J., et al. Int. J. Gastrointest. Cancer 32 (2002) 125-128
14. Nakamura E., Aoki S., Sekiya K., Oshino H., and Kuwajima I. J. Am. Chem. Soc. 109 (1987) 8056-8066
15. Huang M. J. Am. Chem. Soc. 68 (1946) 2487-2488
16. Kawata S., Nagase T., Yamasaki E., Ishiguro H., and Matsuzawa Y. Br. J. Cancer 69 (1994) 1015-1020
17. Sun S.Y., Zhou Z., Wang R., Fu H., and Khuri F.R. Cancer Biol. Ther. 3 (2004) 1092-1098 discussion 1099-1101
18. Hsu Y.L., Kuo P.L., Lin L.T., and Lin C.C. J. Pharmacol. Exp. Ther. 313 (2005) 333-344
19. Park S., Park C.H., Hahm E.R., Kim K., Kimler B.F., et al. Cell. Signalling 17 (2005) 111-119
20. Nguyen T.T., Tran E., Nguyen T.H., Do P.T., Huynh T.H., et al. Carcinogenesis 25 (2004) 647-659
21. Shen G., Xu C., Chen C., Hebbar V., and Kong A.N. Cancer Chemother. Pharmacol. 57 (2006) 317-327
22. Park K.S., Ahn Y., Kim J.A., Yun M.S., Seong B.L., et al. Br. J. Pharmacol. 137 (2002) 597-607
23. Lu M., Xia L., Luo D., Waxman S., and Jing Y. Oncogene 23 (2004) 3945-3952